Protagonist Therapeutics (PTGX) Leases (2019 - 2025)
Historic Leases for Protagonist Therapeutics (PTGX) over the last 7 years, with Q3 2025 value amounting to $8.2 million.
- Protagonist Therapeutics' Leases fell 1688.87% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year decrease of 1688.87%. This contributed to the annual value of $9.4 million for FY2024, which is 88710.69% up from last year.
- According to the latest figures from Q3 2025, Protagonist Therapeutics' Leases is $8.2 million, which was down 1688.87% from $8.6 million recorded in Q2 2025.
- Protagonist Therapeutics' Leases' 5-year high stood at $10.3 million during Q2 2024, with a 5-year trough of $387000.0 in Q1 2024.
- Its 5-year average for Leases is $5.1 million, with a median of $4.5 million in 2022.
- As far as peak fluctuations go, Protagonist Therapeutics' Leases plummeted by 8485.92% in 2024, and later soared by 222558.14% in 2025.
- Protagonist Therapeutics' Leases (Quarter) stood at $4.9 million in 2021, then tumbled by 37.99% to $3.1 million in 2022, then tumbled by 68.83% to $954000.0 in 2023, then surged by 887.11% to $9.4 million in 2024, then decreased by 13.2% to $8.2 million in 2025.
- Its Leases stands at $8.2 million for Q3 2025, versus $8.6 million for Q2 2025 and $9.0 million for Q1 2025.